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Abstract 
Background – Idiopathic intracranial hypertension most commonly affects women of 
childbearing age and usually causes headache and intermittent visual obscurations. 
Some patients suffer permanent visual loss.  The major modifiable risk factor associated 
with IIH is obesity. Scotland has one of the poorest records for obesity in the western 
world with a prevalence in 2016 of 29% in the adult population. We aimed to establish 
the incidence of idiopathic intracranial hypertension (IIH) in Scotland. 
Methods – All new cases of IIH seen in Scotland were collected over a one-year period. 
Cases were reported by ophthalmologists through the Scottish Ophthalmic Surveillance 
Unit (SOSU) and by neurologists directly to the investigators using encrypted NHS 
emails. An open dialogue was maintained between the investigators and specialist 
neuro-ophthalmology clinics throughout the year to minimise the risk of 
underreporting. Cases were defined using the Modified Dandy Diagnostic Criteria. 
Results – One hundred and forty-four confirmed cases of IIH were reported. One 
hundred and ten out of 144 patients were female and aged 15-44. The mean BMI in this 
group was 38.9. 
Conclusions – The incidence of IIH in Scotland is at least 2.65/100,000. This figure 
rises to 37.9/100,000 in obese females aged 15-44. This figure is higher than previously 
published and is probably a result of increasing levels of obesity across the nation. The 
significant morbidity caused by IIH, in this young population raises the question of 
whether enough is being done to prevent and treat Scotland’s obesity crisis.  
Keywords – IIH, obesity, BMI 
Introduction 
Idiopathic intracranial hypertension (IIH) is a syndrome characterised by raised 
intracranial pressure in the absence of clinical, laboratory and radiological evidence of 
a space occupying lesion or hydrocephalus. Its aetiology is unknown, however it 
classically affects young women of childbearing age.1-3 Diagnosis is made based on the 
Modified Dandy Criteria4 and the clinical features, risk factors, natural history and 
long-term follow-up are well described in the literature5. Previous estimates of the 
annual incidence of IIH is varies from 0.03-2.4 per 100,000, however this varies 
depending on ethnicity, geographical location, age and sex (see table 1). IIH is more 
common in women and is predominantly a disease affecting younger adults. The 
estimated incidence in woman aged 15 to 44 years is 3.5/100,000. The most common 
symptoms of IIH are headache and transient visual loss. In the majority of cases, IIH is 
treatable, without impairment of vision in the long term. However, a significant group 
of patients exist who develop permanent visual loss, which can be rapidly progressive 
and devastating.6 
The major modifiable risk factor associated with IIH is body mass7-10. The 
majority of patients with IIH are obese (defined as having a body mass index (BMI) of 
over 30) with an additional link to recent weight gain11.  
Scotland has one of the poorest records for obesity in the western world with a 
prevalence in 2016 of 29% in the adult population12. We have previously performed a 
prospective incidence study of IIH amongst the entire population of Fife, an area on the 
east coast of Scotland with a population of 365,000, and found the incidence to be 
3.56/100,000.13 This is higher than previous studies reporting from similar populations.  
The prevalence of obesity in Fife is only slightly higher than the national average and 
did not account for such a high incidence. As a consequence we decided to undertake a 
nationwide incidence study in Scotland over a period of one year to see if other regions 
in Scotland reflected the findings in Fife as well as to describe the demographics of 
those affected by IIH.  
 
 
Methods 
All new cases of IIH seen by ophthalmologists or neurologists in Scotland were 
collected prospectively between November 1 2016 and October 31 2017. Cases seen 
by ophthalmologists were reported via the Scottish Ophthalmic Surveillance Unit 
(SOSU). SOSU is run by the Royal College of Ophthalmologists, alongside the British 
Ophthalmic Surveillance Unit (BOSU), to assist with the epidemiological study of rare 
ocular disorders. It is an active prospective case ascertainment system that engages with 
all consultant or associate specialist ophthalmologists in Scotland (122 individuals were 
on the database at the time of data collection) to identify cases of rare eye diseases to 
provide meaningful data for epidemiological analysis. Each month, every 
ophthalmologist in Scotland was posted a SOSU reporting card asking if they had 
managed any new cases of IIH in their practice. When a case was reported, a 
questionnaire was sent to the notifying ophthalmologist asking for demographic and 
clinical data on the case, including BMI, medications and postcode. If BMI was not 
known we asked clinicians to comment on whether they considered the patient to be 
clinically obese. If the questionnaire was not returned a reminder letter was sent to 
increase the response rate. Ophthalmologists were also a sent a 6 month follow-up 
questionnaire for each case they reported. An identical system was developed with all 
neurology departments in Scotland. Neurologists were contacted by secure NHS email 
and when a case was reported an abbreviated questionnaire was requesting patient age, 
sex and postcode.  
To maximise case reporting from higher volume specialist neuro-
ophthalmologists, there was a more open dialogue with the investigators, allowing 
cases to be reported by email, rather than being restricted to the SOSU reporting cards. 
Cases of IIH were defined using the the Modified Dandy Criteria, namely: 
 If symptoms and / or signs are present, they may only reflect those of 
generalised intracranial hypertension or papilloedema 
 Intracranial pressure, as measured in the lateral decubitus position, is elevated 
 The composition of the cerebrospinal fluid is normal 
 There is no evidence of hydrocephalus, mass, structural or vascular lesion 
 No other cause of intracranial hypertension has been identified 
Ethics advice was sought from the South East Scotland Research and Ethics 
Service and approval was granted through the Public Benefit and Privacy Panel for 
Health and Social Care in Scotland. 
Population obesity data was taken from the Scottish Health Survey 2016.12 Data 
on social deprivation was analysed depending on postcode using the Scottish Index of 
Multiple Deprivation, also from the Scottish Health Survey 2016. The incidence of IIH 
was calculated using a Scottish population of 5,424,800.14 
 
Results 
206 cases were reported to the investigators during the 12-month study period. Thirty 
of these were excluded, whilst 32 cases were reported by more than one source, leaving 
a total of 144 cases. The breakdown of these case reports is shown in figure 1. Thirteen 
cases were incorrectly reported following errors with the SOSU reporting system and 
so were excluded. Other reasons for exclusion were duplicate reports from the same 
source (8), cases reported outside the study period (4) and incorrect diagnosis (5). 
Twenty-seven of these cases were reported by a neurologist only and therefore only 
age, sex and postcode was collected. Questionnaires were sent for the remaining 117 
cases and 111 responses were received, 106 of which included usable information.  
The SOSU card response rate from ophthalmologists each month was 68%, 
whilst the response rate from neurologists (via email) was 30%. 
Patient demographics 
The mean patient age was 27.7 years with a range of 6 year to 63 years. One hundred 
and ten patients were female and aged 15-44. Eleven patients were under 15 (5 male, 6 
female) and 12 patients were over 44 (2 male, 10 female).  
Obesity 
Information regarding obesity was reported for 103 patients, whilst BMI was available 
for 75. Seventy-three out of 80 (91%) females aged 15-44 were considered to be obese. 
BMIs were reported for 49 patients in this group with a mean of 39.8 (range 17.5 – 
107.3).  43 out of 49 had a BMI greater than 29.9, whilst 47 out of 49 had a BMI of 
greater than 24.9. Five out of 9 children, 5 out of 7 men and 5 out of 7 women over 44 
were considered to be obese.  
Social deprivation 
The distribution of patients by NHS Board and SIMD data is shown in the figure 
2. Vignitile 1 includes the most deprived 5% of the population, whilst vignitile 20 
includes the least deprived 5%. When SIMD data was corrected for obesity, our data 
was did not demonstrate an independent link between social deprivation and IIH. 
Medication use 
Nine patients were taking the oral contraceptive pill, whilst 6 others were 
reported as using alternative forms of long-term contraception (3 intrauterine devices, 
3 contraceptive implants). Five patients were pregnant at the time of diagnosis. Six 
patients reported current or recent use of corticosteroids (1 of these cases was thought 
to be secondary to the use of fludrocortisone) and 4 patients were taking tetracyclines. 
One patient developed IIH following an infusion of intravenous immunoglobulin to 
treat chronic inflammatory demyelinating polyneuropathy. Sixty-nine out of 111 were 
taking no medications prior to their diagnosis. 
One-hundred-and-seven out of 111 patients had bilateral optic disc swelling, 2 
patients had unilateral swelling and 2 patients had normal optic disc appearances. 
Further clinical information and data from the 6-month follow-up questionnaire (which 
was obtained for 103 cases) will be reported in a subsequent article.  
Discussion 
This prospective study estimates that the incidence of IIH in Scotland is 
2.65/100,000. In females aged 15-44 the incidence is 10.7/100,000 and in obese 
females, aged 15-44 the incidence is 37.9/100,000. These figures are significantly 
higher than previously published, which may reflect levels of obesity in Scotland. IIH 
is known to cause significant morbidity, via headache and in some cases irreversible 
loss of vision. Headache is associated with low mood and along with visual loss leads 
to significant psychological, social and economic consequences, magnified by the 
young population that is affected by this condition.15  
A recent meta-analysis16 and systematic review of epidemiological studies in 
IIH highlights significant variability in the incidence of IIH (see table 1) based on 
population characteristics, particularly obesity. They describe a paucity in large, high 
quality epidemiological studies looking at IIH. Very few of the studies they looked at 
were prospective and when compared to all large studies (population size over 
1,000,000) our data for the Scottish population estimates a significantly higher 
incidence.  
The demographics of our study were consistent with the literature, with the 
majority of cases affecting women, aged 15-44. Mean BMI of 39.8 is also consistent 
with previous studies. BMI was not recorded for 36 out of 111 cases (33%). The 
recently published consensus guidelines on IIH identify weight loss as the only disease 
modifying therapy in typical IIH, advising that BMI should be recorded at all follow-
up appointments. Patients with IIH often struggle to lose weight. Regular BMI 
monitoring in clinic may serve as a reminder and promote discussion about the 
importance of weight loss in managing IIH, taking emphasis away from the medications 
that often demand much attention during a consultation but do not in fact modify the 
course of the disease.  
This data adds further weight to evidence from many other medical specialties 
that Scotland’s obesity epidemic is causing significant morbidity, and raises the 
question about whether enough is being done at a public health level to reverse the 
trend. 
Our study is the first to show that IIH is most prevalent in areas of social 
deprivation. It is likely that higher levels of obesity in these areas explain this link. 
Indeed, when we analysed our results, corrected for obesity, social deprivation was not 
an independent risk factor for IIH. It is interesting to note that the number of cases 
reported drop off in the 2 most deprived vigintiles. This almost certainly reflects under-
reporting due to lack of engagement with or lack of access to health services in these 
populations.17 
Whilst the pathogenesis is not full understood it is thought that ‘prepubertal’ 
IIH and ‘secondary’ IIH, linked to medication use, are distinct conditions from typical 
‘weight-related’ IIH.15 Eleven cases of IIH were reported in patients under 15 years-old 
(male:female = 6:5), although we did not specifically ask if these individuals were 
prepubertal. The male to female ratio in prepubertal IIH is nearly one, a condition that 
may not be associated with weight. Of the nine reported cases that included information 
about obesity, five (55%) were considered to be obese. 
The number of cases in our study is not sufficient to reach a conclusion on the 
role that individual medications play in the pathogenesis of IIH. Nine out of 111 patients 
(8.1%) were taking the oral contraceptive pill at the time of diagnosis. There is 
conflicting evidence linking oral contraception and IIH. Recent consensus suggests that 
similar to pregnancy, it is likely that this relationship reflects the typical age and gender 
profile of an IIH patient rather than the medication itself.1,7,8 Five patients (4.5%) were 
pregnant at the time of diagnosis. As with oral contraceptive use, a seemingly high 
prevalence of IIH during pregnancy is thought to reflect young, female demographic 
affected. It is likely that patients diagnosed during pregnancy likely had onset of IIH 
prior to getting pregnant. Our experience suggests that IIH often stabilises during 
pregnancy despite stopping treatment.18 
Of the six patients that reported current or recent use of corticosteroids 2 were 
male, and one female was over 44. Only one of these patients was obese (female aged 
15-44). Secondary IIH has been reported with corticosteroid excess and also with 
deficiency (such as in Addison’s disease) although this link is not established.15 All four 
patients that were taking tetracylines were females, aged between 15 and 44 who were 
obese. IIH has been reported in patients taking tetracycline antibiotics in many case 
reports and in one case-control study, however other prospective studies have failed to 
confirm this link.1,8,11 One patient developed IIH following an infusion of intravenous 
immunoglobulin to treat chronic inflammatory demyelinating polyneuropathy. If these 
cases are truly linked to medication then they should be considered as secondary IIH, 
which should be considered differently to weight associated IIH. 
It must be true that the true incidence of any condition, with specific diagnostic 
criteria, that is the subject of a study that relies on case reporting will be equal to or 
higher than the reported figure. The main reason for this is under-reporting. Response 
rates from ophthalmologists and neurologists were similar to previous BOSU/SOSU 
studies and other electronic case reporting studies respectively. By receiving case 
reports from multiple sources (neurology, ophthalmology and specialist neuro-
ophthalmologists) we attempted to minimise under-reporting. Our data shows a 
significant variation in cases reported depending on NHS board across Scotland. In 
smaller NHS boards, the population is such that 1 or 2 new cases will significantly 
change the incidence per 100,000 and so a study period of 1 year does not accurately 
reflect the incidence. The variation seen between the larger health boards (most 
noticeable when comparing Lothian and Tayside) probably reflects under-reporting, 
where busy clinicians fail to report cases they have seen.  
 The Modified Dandy Criteria were used to define the diagnosis of IIH in our 
study. In reality the diagnosis is often not straightforward, which is reflected in recently 
published consensus guidelines.15 This is further highlighted by Fisayo et al19 who 
suggest that IIH is often over-diagnosed, despite the Modified Dandy Criteria. Their 
retrospective study showed that a significant proportion of patients initially diagnosed 
with IIH by non-neuro-ophthalmologists (including ophthalmologists, neurologists and 
optometrists) did not have IIH, according to the neuro-ophthalmologist. They cited the 
most common source of error was inaccurate assessment of the optic nerve head, 
(usually anomalous optic nerves being misinterpreted as papilloedema). Mild optic disc 
swelling from papilloedema can be a subtle sign and an asymptomatic patient, with 
normal imaging, can be observed by experienced clinicians, rather than proceeding with 
an invasive lumbar puncture.  
Our study design was such that false positives were unlikely. Eighty-two out of 
144 new cases were reported by specialist neuro-ophthalmologists. Six month follow-
up data was available for 103 cases, none of whom had their diagnosis revised. We are 
unable to comment on the diagnostic accuracy of the 27 cases reported by neurology 
only, however it is likely that most (if not all) of these will have also been seen by an 
ophthalmologist, with the that fact they were reported by neurology only, reflecting 
under-reporting by ophthalmologists.  
Furthermore, in certain cases measuring opening pressure by lumber puncture 
can be unreliable. It is important to follow a standard protocol when obtaining an 
opening pressure, to avoid inaccurate results. LP can be more difficult in obese patients, 
where bony landmarks are less obvious, anxiety, leading to tense muscles can alter true 
CSF pressure. If LP opening pressure does not fit the clinical picture, it should be 
interpreted with caution. For clarity and consistency, elevated opening pressure on LP 
was an essential part of the inclusion criteria in our study, which may have resulted in 
underreporting caused by false negatives.  
Although our figure of 2.65 cases of IIH for 100,00 of the population is almost 
certainly an underestimate, it is clear that the incidence of is increasing, alongside 
increasing levels of obesity throughout Scotland. We have shown that the incidence of 
IIH in Scotland is at least 2.65/100,000, which rises to 40 per 100,000 in obese young 
women. Frustratingly, for most of people IIH should be preventable. Our study is the 
latest in a long line, showing increased morbidity caused by Scotland’s obesity crisis 
and raises questions about whether we, as a society, are doing enough to prevent and 
treat this modern epidemic. 
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Table 1. Published Incidence of IIH in the literature 
 
(see separate document for table 1, due to formatting) 
 
Table 2. Patient demographics showing obesity and BMI data  
  
 
 
 
 
 
 
 
 
 
Figure 1. Source of reported new cases of IIH 
 Number 
(n=141) 
Patients considered to be 
clinically obese 
Mean BMI (range) 
Female < 15 6 4/4 (100%) 28.5 (1 reported) 
Male < 15 5 1/5 (20%) 20.99 (16.64-16.28 
Female 15-44 110 73/80 (91%) 39.8 (17.5-107.3) 
Male 15-44 8 5/6 (83%) 39.0 (28.7-47.9) 
Female > 44 10 5/7 (71%) 39.4 (24.2-56.5) 
Male > 44 2 0/1 (0%) n/a 
  
Figure 2. Number of cases of IIH shown by healthboard, per 100000 of population 
and per SIMD viginitle. Vigintile 1 is the most deprived 5% of the population. 
 
